You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

recurrent carcinoma of unknown primary

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Head and Neck Carcinoma of Unknown Primary, Locally Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Laryngeal

Recruiting
  • Head and Neck Carcinoma of Unknown Primary
  • +5 more
  • External Beam Radiation Therapy
  • +4 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Dec 1, 2022

Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma,

Recruiting
  • Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
  • +24 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
May 18, 2022

Cancer of Unknown Primary Site, Unknown Primary Cancer, Unknown Primary, Squamous Cell Carcinoma Trial in Copenhagen, Århus

Recruiting
  • Cancer of Unknown Primary Site
  • +2 more
  • Transoral Ultrasound
  • Copenhagen, Denmark
  • +1 more
May 2, 2023

Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With

Completed
Has Results
  • Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma
  • +35 more
  • PI3K inhibitor BKM120
  • cetuximab
  • Chicago, Illinois
    University of Chicago Comprehensive Cancer Center
Sep 14, 2021

Circulating Biomarkers in Oropharyngeal Cancers

Active, not recruiting
  • Oropharynx Squamous Cell Carcinoma
  • +3 more
    • Orebro, Sweden
      Anna Oldaeus Almerén
    Jun 13, 2023

    Carcinoma of Unknown Primary: A Comparison Across Tissue and

    Recruiting
    • Cancer of Unknown Primary Site
      • Bath, United Kingdom
      • +6 more
      Oct 18, 2022

      Carcinoma of Unknown Primary Trial in Calgary, Edmonton, Ottawa (Pembrolizumab Injection)

      Recruiting
      • Carcinoma of Unknown Primary
      • Pembrolizumab Injection
      • Calgary, Alberta, Canada
      • +2 more
      Feb 18, 2022

      Adenoid Cystic Skin Carcinoma, Adnexal Carcinoma, Anaplastic Large Cell Lymphoma, ALK-Negative Trial in United States

      Recruiting
      • Adenoid Cystic Skin Carcinoma
      • +38 more
      • Biopsy
      • +6 more
      • Los Angeles, California
      • +35 more
      Jan 31, 2023

      Head Neck Cancer, Unknown Primary Cancer, Head and Neck Squamous Cell Carcinoma Trial in Dallas (Pegsitacianine)

      Not yet recruiting
      • Head and Neck Cancer
      • +2 more
      • Dallas, Texas
        University of Texas Southwestern Medical Center
      Jan 18, 2023

      Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

      Completed
      Has Results
      • Platinum-Resistant Fallopian Tube Carcinoma
      • +8 more
      • Bevacizumab
      • Irinotecan Sucrosofate
      • Chicago, Illinois
        Northwestern University
      Dec 21, 2022

      Analgesia, Surgery, Cancer of Head and Neck Trial in Copenhagen (Dexamethasone, Placebo)

      Active, not recruiting
      • Analgesia
      • +6 more
      • Copenhagen, Denmark
        Department of Otorhinolaryngology, Head and Neck Surgery & Audio
      Oct 14, 2022

      Fallopian Tube Carcinosarcoma, Primary Peritoneal Carcinosarcoma, Recurrent Fallopian Tube Carcinoma Trial in Rochester (Biopsy,

      Not yet recruiting
      • Fallopian Tube Carcinosarcoma
      • +14 more
      • Biopsy
      • +6 more
      • Rochester, Minnesota
        Mayo Clinic in Rochester
      Jun 28, 2023

      A Prospective, Randomized Controlled Study of Cyclophosphamide,

      Not yet recruiting
      • Epithelial Ovarian Cancer
      • Shijiazhuang, Hebei, China
        Hebei
      Aug 20, 2023

      BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ovarian Serous Adenocarcinoma Trial in Buffalo, New York (biological, other, drug)

      Active, not recruiting
      Has Results
      • BRCA1 Gene Mutation
      • +5 more
      • Durvalumab
      • +3 more
      • Buffalo, New York
      • +1 more
      Jan 20, 2023

      Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma, Platinum-Refractory Primary Peritoneal

      Recruiting
      • Platinum-Refractory Fallopian Tube Carcinoma
      • +11 more
      • Copanlisib Hydrochloride
      • +4 more
      • Aurora, Colorado
      • +2 more
      Dec 8, 2022

      Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma Trial in Boston, Houston

      Recruiting
      • Recurrent Fallopian Tube Carcinoma
      • +2 more
      • Boston, Massachusetts
      • +1 more
      Jan 12, 2023

      Squamous Cell Carcinoma of the Oropharynx, Squamous Cell Carcinoma, Unknown Primary Trial in Liverpool (Versius Surgical System)

      Not yet recruiting
      • Squamous Cell Carcinoma of the Oropharynx
      • Squamous Cell Carcinoma, Unknown Primary
      • Versius Surgical System
      • Liverpool, United Kingdom
        Liverpool Head and Neck Centre, ENT Department Liverpool Univers
      Oct 27, 2023

      Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Endometrial Adenocarcinoma Trial in Houston (Copanlisib,

      Recruiting
      • Deleterious BRCA1 Gene Mutation
      • +10 more
      • Houston, Texas
        M D Anderson Cancer Center
      Aug 23, 2022

      Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

      Recruiting
      • Platinum-Resistant Fallopian Tube Carcinoma
      • +6 more
      • Columbus, Ohio
        Ohio State University Comprehensive Cancer Center
      May 17, 2022

      Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

      Not yet recruiting
      • Platinum-Resistant Fallopian Tube Carcinoma
      • +5 more
      • Biopsy
      • +4 more
      • Duarte, California
        City of Hope Medical Center
      Jan 3, 2023

      Solid Tumor, Microsatellite Instability, Mismatch Repair Deficiency Trial in Australia (APL-501)

      Completed
      • Solid Tumor
      • +3 more
      • Camperdown, New South Wales, Australia
      • +4 more
      May 5, 2022

      Ovarian Cancer, Epithelial Trial in Nanjing (Envafolimab, Lenvatinib, VP-16)

      Not yet recruiting
      • Ovarian Cancer, Epithelial
      • Nanjing, Jiangsu, China
        Zhongda Hospital
      Jun 13, 2022

      BRCA1 Gene Mutation, BRCA2 Gene Mutation, Folate Receptor Alpha Positive Trial in Columbus (other, biological, drug)

      Active, not recruiting
      • BRCA1 Gene Mutation
      • +9 more
      • Laboratory Biomarker Analysis
      • +3 more
      • Columbus, Ohio
        Ohio State University Comprehensive Cancer Center
      Sep 16, 2022

      Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

      Recruiting
      • Platinum-Resistant Fallopian Tube Carcinoma
      • +8 more
      • Durvalumab
      • Tremelimumab
      • Houston, Texas
        M D Anderson Cancer Center
      Jul 19, 2022

      Integrated Molecular Profiling in Advanced Cancers Trial

      Active, not recruiting
      • Breast Cancer
      • +9 more
        • Toronto, Ontario, Canada
          Princess Margaret Hospital
        Sep 26, 2022